Table 3 General characteristics of IRB protocols
Number of protocols N (%) | |
|---|---|
(n = 240) | |
Population proposed for investigation | |
Males | 8 (3.3) |
Females | 26 (10.8) |
Both | 205 (85.4) |
Not applicable | 1 (0.4) |
Type of IRB review | |
Full | 209 (87.1) |
Expedited | 26 (10.8) |
Exempt | 5 (2.1) |
Type of data to be studied | |
New data | 231 (96.3) |
Existing population database | 9 (3.8) |
Funding source | |
No funding | 57 (23.8) |
National Institutes of Health | 30 (12.5) |
Foundation | 15 (6.3) |
Penn Internal Grant or Funds | 12 (5.0) |
Pharmaceutical | 91 (37.9) |
Other funding | 42 (17.5) |
Mention of keywords | |
Mention “sex” or “gender” | 45 (18.8) |
Mention “male,” “female,” “men,” or “women” | 155 (64.6) |
Mention at least one of the following: “sex,” “gender,” “male,” “female,” “men,” and “women” | 165 (68.8) |
Area of investigation | |
Behavioral/neurological/psychological | 46 (19.2) |
Medicine | 70 (29.2) |
Surgery | 35 (14.6) |
Oncology | 73 (30.4) |
Obstetrics and gynecology | 9 (3.8) |
Genetics | 4 (1.7) |
Pediatrics | 3 (1.3) |
Location of keywords within protocol | |
(n = 165) | |
Objectives | 17 (10.3) |
Background | 19 (11.5) |
Study design | 12 (7.3) |
Populations | 32 (19.4) |
Inclusions/exclusions | 142 (86.1) |
Procedures | 8 (4.8) |
Other | 6 (3.6) |